{"schema_version":"secwatch.filing_event.v1","accession":"0001000228-25-000042","form_type":"8-K","ticker":"HSIC","cik":"0001000228","company_name":"HENRY SCHEIN INC","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.098730+00:00","generated_at":"2026-05-17T20:20:27.814718+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Henry Schein Q2 GAAP EPS $0.70 (down 12.5% YoY); maintains FY25 guidance","bullets":["Q2 GAAP net income $86M ($0.70 diluted EPS) vs $104M ($0.80) YoY; non-GAAP EPS $1.10 vs $1.23.","Total sales $3.2B, up 3.3% as-reported; internal growth 1.9%; Global Medical Distribution up 6.1%.","Adjusted EBITDA $256M vs $268M; recorded $23M restructuring costs targeting $100M+ annual run-rate savings.","FY25 guidance maintained: non-GAAP diluted EPS $4.80-$4.94, sales growth 2%-4%, mid-single digit Adj. EBITDA growth.","Repurchased ~3.7M shares for $259M in Q2; $432M remaining for future repurchases."],"urls":{"canonical":"https://secwatch.observer/filing/0001000228-25-000042","json":"https://secwatch.observer/filing/0001000228-25-000042.json","markdown":"https://secwatch.observer/filing/0001000228-25-000042.md","text":"https://secwatch.observer/filing/0001000228-25-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000228/000100022825000042/0001000228-25-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000228/000100022825000042/hsic-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:20:27.814718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}